Market revenue in 2023 | USD 155.4 million |
Market revenue in 2030 | USD 235.6 million |
Growth rate | 6.1% (CAGR from 2023 to 2030) |
Largest segment | Phase iii |
Fastest growing segment | Phase I |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Phase I, Phase II, Phase III, Phase IV |
Key market players worldwide | Novartis AG ADR, Labcorp Holdings Inc, Medpace Holdings Inc, Charles River Laboratories International Inc, Icon PLC, GlaxoSmithKline Consumer Healthcare (GSK CH India), Aurora Innovation Inc Class A, Biogen Inc, IQVIA Holdings Inc, inVentiv Health |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to neurology clinical trials market will help companies and investors design strategic landscapes.
Phase iii was the largest segment with a revenue share of 49.87% in 2023. Horizon Databook has segmented the South Korea neurology clinical trials market based on phase i, phase ii, phase iii, phase iv covering the revenue growth of each sub-segment from 2018 to 2030.
South Korea has a world-class medical infrastructure and is a popular location for neurology clinical trials. Their researchers are typically involved in clinical trials and are enthusiastic about contributing to clinical innovation. The trials are typically held in well-equipped hospitals where adherence is maintained by a high level of professionalism and a culture of profound respect between both patients and physicians.
It is a country that views high-quality studies as a long-term investment in its people's future. As a result, it offers a variety of inducements to encourage investment in the country's clinical trials sector. Recently, several e-resources have been incorporated. For instance, a clinical trial eregistration system is immediately available following IND approval as well as a self-registration structure for CROs.
It is still an excellent location for conducting clinical trials. Everyone works together to ensure that a trial is completed on time and with high quality, from the country's progressive structural response to the elevated quality of its trial sites and clinical adherence culture.
Horizon Databook provides a detailed overview of country-level data and insights on the South Korea neurology clinical trials market , including forecasts for subscribers. This country databook contains high-level insights into South Korea neurology clinical trials market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account